AMRN: Amarin Corporation plc - Summary | Jitta

Amarin Corporation plc

NASDAQ:AMRN

Price
$14.24
Loss Chance
47.9%
3.77JITTA SCORE
21.60%Over Jitta Line
Jitta Ranking
127 / 717
1,415 / 4,223
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (48)
Recent Business Performance (82)
Financial Strength (54)
Return to Shareholders (1)
Competitive Advantage (36)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
SG&A to SalesDecreasing
Revenue and EarningEarning loss detected in 2024
Operating MarginInconsistent
Cash Conversion CycleMore than 1 year
Key Stats
Jitta Score
Jitta Line
3.77
21.60%
2.24
183.94%
3.07
432.53%
Biotechnology
5.32
39.07%
1.82
73.65%
1.82
73.65%
COMPANY DESCRIPTION
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.